VectorY Therapeutics Secures €74.5 Million to Accelerate ALS and Huntington’s Disease Programmes
Amsterdam‑based VectorY Therapeutics, a biotech developing vectorised antibody therapies for neurodegenerative diseases, closed a €74.5 million financing round with participation from new and existing investors. The funds will be used to push its lead ALS programme forward and expand its pipeline into Huntington’s disease and other conditions.